MedWorm.com provides a medical RSS filtering service. Over 5000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous' source. Sat, 16 Aug 2008 14:48:16 +0100 http://www.rosacea.md/?p=11 The emotional suffering rosacea may cause those who have it can be severe, but a new study also showed that the cost of rosacea to taxpayers may also be significant. A study by Ohio State University researchers tracked 2,587 patients with rosacea prescriptions to follow their refill adherence. The study showed some interesting results. According to the researchers: “Patients’ healthcare costs increased with increasing age and charges paid for prescriptions. Topical metronidazole seems to be an economically feasible treatment option for Medicaid-enrolled patients with rosacea.” The study also showed that non-white patients also were less likely to refill their prescriptions. “Patients’ demographic characteristics, number of metronidazole refills, and different components of healthcare costs were examined. Results: Out of the total 2587 rosacea patients, the majority ( approximately 69%, n = 1771) had one or more prescriptions for topical metronidazole. Most of the patients in this study were white (73%). After controlling for other variables, increasing age was associated with a higher number of metronidazole refills and healthcare costs (both p<0.001). Compared with white patients, African American patients had a significantly lower number of metronidazole refills (p<0.001). Compared with white patients, African American patients and ‘other’ races were associated with an 8.6% and 10.3% decrease in total healthcare costs respectively (both p<0.001).” Interestingly they found that an increase in the metronidazole refills was not associated with an increase in healthcare costs. (Source: The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous) The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous blogs http://www.medworm.com/rss/comments.php?id=1642759 Tue, 22 Jul 2008 02:38:06 +0100 1642759 http://www.rosacea.md/?p=10 A new study in the Journal Lasers in Surgery and Medicine by renowned dermatologic researchers Drs. Albert Kligman and Eric Bernstein report on a new 595 nm long pulse-duration pulsed-dye laser for the treatment of rosacea. The results are very promising. The study included twenty subjects with rosacea. Following treatment the subjects were evaluated and the results were: The average rosacea score as estimated by the treating physician decreased from 2.7+/-1.1 to 1.4+ 0.7 (mean+SD) on a 0-6 scale with 0 representing no rosacea and 6 representing the most severe rosacea (P<0.001 level). The average rosacea score as rated by blinded physician observers scoring digital photos was 2.3+/-1.3 before treatment and 1.4+/-0.9 8 weeks following treatment, using a 0 (mild) to 6 (severe) scale. CONCLUSIONS: The high-energy, long pulse-duration pulsed-dye laser improves rosacea with a very favorable safety profile, and less purpura than resulted from earlier generation pulsed-dye lasers. The safety and efficacy of this treatment are very promising indeed for those suffering with rosacea. Proper laser treatment holds great promise for these patients. (Source: The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous) The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous blogs http://www.medworm.com/rss/comments.php?id=1382488 Fri, 18 Apr 2008 19:46:33 +0100 1382488 http://www.rosacea.md/?p=9 A new study from the San Gallicano Dermatologic Institute in Rome shows that a topical treatment based on silymarin/methylsulfonilmethane (S-MSM) can be effective in treating stage I-III rosacea patients. Drs. Berardesca et al used the topical medications on 46 patients over 30 days in a double-blind, placebo controlled study. Instrumental evaluations were done after 10 and 20 days to measure itching, stinging, erythema, papules, as well as hydration and erythema.   The study reports:   “A statistically significant improvement was observed in many clinical and instrumental parameters investigated (P < 0.001). In particular, improvement of skin redness, papules, itching, hydration, and skin color occurred.   Conclusions The combination of silymarin and S-MSM can be useful in managing symptoms and condition of rosacea skin, especially in the rosacea subtype 1 erythemato-telangiectatic phase. The action can be considered multicentric and multiphase because of the direct modulating action on cytokines and angiokines normally involved and up-regulated in the case of such skin condition.”   The further research into both topical and laser/light based treatments shows a great deal of promise for sufferers of rosacea. (Source: The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous) The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous blogs http://www.medworm.com/rss/comments.php?id=1223761 Mon, 11 Feb 2008 21:34:58 +0100 1223761 http://www.rosacea.md/?p=8 The flushing and redness associated with rosacea is treated effectively with laser therapy, this has been known for almost a decade. A new study released by researchers from the University of Copenhagen analyzed photodynamic therapy (PDT) for the treatment of rosacea.   The reported method and results:   Routine MAL-PDT with methylaminolevulate and red light was given one to four times; results were evaluated 1-2 months after PTD was initiated and subsequently followed up.   Results Good results were seen in 10 out of 17 patients, and fair results in another 4 patients. The majority of patients treated could stop or significantly reduce other rosacea therapy for a period lasting from about 3 months and up to 2 years. The study is limited by strong selection bias, and the clinical evaluation was obtained from case notes and photos.   Due to the selection bias, the authors recommend a future randomized trial. Has anyone any comments on this?   (Source: The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous) The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous blogs http://www.medworm.com/rss/comments.php?id=954240 Tue, 16 Oct 2007 02:02:59 +0100 954240 http://www.rosacea.md/?p=6 In certain cases, the papulopustular and telangiectatic components of rosacea are unresponsive to traditional antibiotics treatments. In a recent study, Larson AA, Goldman MP, in conjunction with Dermatology Section of Dartmouth-Hitchcock Medical Center in Lebanon, NH, have presented a case that was unresponsive to treatment with antibiotics. In response, they utilized the multiplexed laser for treatment of both papular and telangiectatic rosacea with success. Laser treatment of the redness and telangiectatic components of rosacea has recently been very popular. Dr. Eric Bernstein has demonstrated highly effective results with his treatment with laser. Does anyone have any results, or experiences with recalcitrant rosacea being treated with laser therapy? (Source: The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous) The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous blogs http://www.medworm.com/rss/comments.php?id=858470 Thu, 06 Sep 2007 21:12:00 +0100 858470 http://www.rosacea.md/?p=5 For many years the tetracycline drugs have been prescribed for sufferers of rosacea, though we were not exactly sure why these drugs were effective. The conventional wisdom has been that this class of drugs works on rosacea due to its anti-inflammatory properties, as well as having some impact on papulopustular rosacea and its associated acne-like symptoms. CollaGenex Pharmaceuticals Inc of Newtown, PA., has now published a study by Theobald K, Bradshaw M, and Leyden J. demonstrating the efficacy of a 40-mg controlled-release formulation of doxycycline in the treatment of rosacea, a dose well below the conventional level of 100 to 200 mg/d. Since no formal dose-response studies have been conducted, the authors analyzed phase 3 data to determine whether a dose-efficacy relationship exists. Their methods involved standard parametric regression analyses were used to estimate the correlations between dose (mg/kg body weight) and overall drug exposure (area under the curve [AUC]) in a phase 1 pharmacokinetic study and between dose and efficacy (mean change from baseline in total inflammatory lesion count at week 16) in 2 pooled phase 3 clinical efficacy studies. Additional regressions were run at each visit for the clinical efficacy studies to determine whether results differed across visits. A regression analysis was also performed in a subset of patients who showed a greater efficacy response. Results. We found overall drug exposure (AUC) to have a highly significant correlation with dose (mg/kg) (r=0.49; P=.006). In contrast, clinical efficacy did not correlate with dose at any of the visits at week 3 (r=0.01; P=.85), week 6 (r=0.04; P=.53), week 12 (r<0.01; P=.98), and week 16 (r=0.03; P=.64) or among the subset of patients who showed greater clinical benefit. Their conclusions are that higher doses did not lead to any increased efficacy. Their results showed that 40-mg controlled-release formulation conferred peak anti-inflammatory efficacy in the treatment of rosacea Has anyone seen anecdotal evidence to support this? Or counter it? Thanks for your comments. (Source: The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous) The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous blogs http://www.medworm.com/rss/comments.php?id=858471 Sat, 18 Aug 2007 20:26:05 +0100 858471 http://www.rosacea.md/?p=4 Welcome fellow dermatologists! Finally we have a physician resource to discuss our experiences treating, managing and understanding Rosacea. We have established this forum as a place for us to interact, deposit knowledge and methods, observations, and advice from a physician’s point of view. Rosacea is a complex and often misdiagnosed condition. Management of symptoms and treatment recommendations can be contentious and hotly debated. Our hope is that by created a resource for physicians internationally, we may all garner a greater understanding of what is needed and what is possible in our research and treatment of this condition. We invite visitors to post and physicians to join our blog roll. Eventually this site will become a quality resource for patients as well. Best Regards, The Moderators (Source: The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous) The Rosacea Forum - Papulopustular, Telangiectatic, and Phymatous blogs http://www.medworm.com/rss/comments.php?id=858472 Mon, 23 Jul 2007 00:30:44 +0100 858472